MADRIGAL PHARMACEUTICALS, INC. · Exercise / conversion · Common Stock

What does this filing report?

An SEC Form 4 filing for MADRIGAL PHARMACEUTICALS, INC. records an exercise / conversion involving Common Stock on December 2, 2025. The reported quantity was 4,173. The filing date is December 3, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Filing footnotes & remarks

F1

These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 2, 2025.

F2

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $570.17 to $570.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.

F3

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $571.45 to $572.34, inclusive.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $572.48 to $573.38, inclusive.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $573.59 to $574.44, inclusive.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $574.67 to $575.24, inclusive.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $575.69 to $576.46, inclusive.

F8

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $577.36 to $578.31, inclusive.

F9

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $578.37 to $579.20, inclusive.

F10

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $579.59 to $580.46, inclusive.

F11

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $585.08 to $585.99, inclusive.

F12

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $587.58 to $588.07, inclusive.

F13

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $589.13 to $589.96, inclusive.

F14

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $590.15 to $590.58, inclusive.

F15

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $595.18 to $595.41, inclusive.

F16

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $596.18 to $596.19, inclusive.

F17

All shares issued pursuant to the exercise of the options reported herein represent 4,173 shares underlying an overall option award of 13,353 shares. All exercised options had vested. As to the overall option for 13,353 shares, 25% of the shares vested on March 1, 2025, and, thereafter, 6.25% of the shares vested or will vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.